Aerie Pharmaceuticals Inc P/E
Cos'è P/E di Aerie Pharmaceuticals Inc?
P/E di Aerie Pharmaceuticals Inc è 0.00
Qual è la definizione di P/E?
Il rapporto prezzo / utili è il rapporto tra il prezzo delle azioni di una società e l'utile per azione della società calcolato su dodici mesi.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E di aziende nel Health Care settore su NASDAQ rispetto a Aerie Pharmaceuticals Inc
Cosa fa Aerie Pharmaceuticals Inc?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Aziende con p/e simili a Aerie Pharmaceuticals Inc
- Richland Resources International ha P/E di N/A
- Safeplus International ha P/E di N/A
- China Yanyuan Yuhui Natl Ed Grp ha P/E di N/A
- Acusphere ha P/E di N/A
- American Oriental Bioengineering ha P/E di N/A
- Gourmet Provisions International ha P/E di N/A
- Aerie Pharmaceuticals Inc ha P/E di 0.00
- SEL Manufacturing ha P/E di 0.00
- China Zhong Qi Hldgs ha P/E di 0.00
- MedSmart ha P/E di 0.00
- Panbela Therapeutics ha P/E di 0.00
- Epic ha P/E di 0.00
- 2574 ha P/E di 0.00